Clinical Trials Network
Reducing barriers in autism research, in clinical trials and beyond
Why are networks helpful in reducing barriers for clinical trials?
Clinical trials are often prohibitively expensive to conduct, requiring months-long recruitment of interested participants, preparation of new lab equipment, and training researchers in new methods. Building on the framework of the Clinical Trials Network (CTN) developed in EU-AIMS, the AIMS-2-TRIALS consortium aimed to reduce the cost of and time taken to complete clinical trials through a multi-pronged approach to address the multistakeholder nature of autism research.
What was achieved in AIMS-2-TRIALS?
The European Autism GEnomics Registry (EAGER) was set up as part of the AIMS-2-TRIALS Clinical Trials Network to build a lasting community of participants who have agreed to be contacted about future research. Researchers can work with EAGER sites to reach people who have agreed to hear about new research opportunities. Throughout this work community engagement was a key focus to optimise the design and implementation of the study. For more information regarding the ongoing network for clinical research please see the European Autism GEnomics Registry (EAGER) page.
AIMS-2-TRIALS has generated networks to achieve the following:
- Facilitated involvement in clinical trials and collaborative European-wide research projects through the previous CTN and ongoing EAGER networks.
We created a network of potential research partner sites which facilitated and accelerated involvement in industry-led clinical trials in autism and initiated joint research projects – e.g. COVID-19 health and social care access for autistic people and individuals with intellectual disability: A European policy review. - Improved opportunities for networking and training
We developed a network of early-career researchers – over 120 scientists joined our network and have benefitted from access to training opportunities. Training covered topics including statistics, communication, community engagement (co-designed by A-Reps), biomarker development and data infrastructure. We organised both webinars and satellite meetings at conferences to facilitate collaboration and generate networking opportunities, including a Co-Creation Masterclass in Prague before INSAR 2026. - Enhanced communication and dissemination:
Disseminated research outputs including new publications, research summaries (link to news page), newsletters and project outreach activities.
What was the Clinical Trials Network?
To address training and lab preparation and training requirements the Clinical Trials Network (CTN) was created as a proof of concept to connect and train multiple sites across Europe to be trial-ready. The CTN connected over 120 sites across 37 countries, successfully facilitating multi-center studies through a single point of contact. Clinicians and researchers successfully accessed training and education around autism and clinical trials, enhancing services that families receive in their local centers.
Objectives
1. Establish a network trained to international standards to ensure the safety, integrity, and quality of autism trials conducted
2. Ensure that the network will be sustainable in the future
3. Train the next generation of leaders to design and conduct world-leading trials of treatments







